Analysts are on the Bearish side about Antares Pharma, Inc. (NASDAQ:ATRS) this week.

January 12, 2018 - By Marie Mckinney

 Analysts are on the Bearish side about Antares Pharma, Inc. (NASDAQ:ATRS) this week.
Investors sentiment decreased to 1.29 in 2017 Q3. Its down 0.78, from 2.07 in 2017Q2. It dropped, as 11 investors sold Antares Pharma, Inc. shares while 23 reduced holdings. 18 funds opened positions while 26 raised stakes. 53.56 million shares or 0.15% less from 53.64 million shares in 2017Q2 were reported.
Legal & General Gp Inc Plc stated it has 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Guggenheim Cap Ltd Limited Liability Company holds 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS) for 408,944 shares. Barclays Plc stated it has 136,338 shares. Hightower Advsr Ltd Co invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Manufacturers Life Ins The accumulated 119,903 shares. Rhumbline Advisers reported 150,288 shares. California State Teachers Retirement System reported 228,385 shares. Morgan Stanley stated it has 830,309 shares or 0% of all its holdings. 80,791 are held by Nationwide Fund. Baystate Wealth Management Ltd Liability Co owns 1,397 shares. Voya Invest Mgmt Limited Co holds 0% or 65,073 shares. Atlantic Grp Ltd reported 125,000 shares or 0% of all its holdings. Avenir Corp has 351,685 shares for 0.1% of their portfolio. The New York-based First Eagle Inv has invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). 64,737 are held by Planning.

Since October 3, 2017, it had 0 buys, and 2 sales for $1.04 million activity. Another trade for 30,000 shares valued at $105,000 was sold by GARRITY THOMAS J.

Antares Pharma, Inc. (NASDAQ:ATRS) Ratings Coverage

Among 4 analysts covering Antares Pharma (NASDAQ:ATRS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Antares Pharma had 10 analyst reports since March 9, 2016 according to SRatingsIntel. The firm earned “Buy” rating on Friday, September 8 by H.C. Wainwright. H.C. Wainwright initiated Antares Pharma, Inc. (NASDAQ:ATRS) rating on Friday, June 23. H.C. Wainwright has “Buy” rating and $500 target. Piper Jaffray maintained the shares of ATRS in report on Tuesday, July 25 with “Buy” rating. The firm has “Buy” rating given on Monday, October 23 by Piper Jaffray. The firm has “Buy” rating by Jefferies given on Monday, August 7. Jefferies maintained the stock with “Buy” rating in Wednesday, March 9 report. The firm earned “Buy” rating on Tuesday, October 10 by Jefferies. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, November 8. The firm has “Buy” rating by H.C. Wainwright given on Monday, October 23. Below is a list of Antares Pharma, Inc. (NASDAQ:ATRS) latest ratings and price target changes.

08/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $3.5 Maintain
23/10/2017 Broker: H.C. Wainwright Rating: Buy New Target: $3.5 Maintain
23/10/2017 Broker: Piper Jaffray Rating: Buy New Target: $3.0 Maintain
10/10/2017 Broker: Jefferies Rating: Buy New Target: $6.0 Maintain
08/09/2017 Broker: H.C. Wainwright Rating: Buy New Target: $5.0 Initiate
07/08/2017 Broker: Jefferies Rating: Buy New Target: $6.0000 Maintain
25/07/2017 Broker: Piper Jaffray Rating: Buy New Target: $4.0000 Maintain

The stock decreased 0.85% or $0.0195 during the last trading session, reaching $2.2705. About 707,753 shares traded. Antares Pharma, Inc. (NASDAQ:ATRS) has risen 207.14% since January 12, 2017 and is uptrending. It has outperformed by 190.44% the S&P500.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company has market cap of $355.73 million. The companyÂ’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It currently has negative earnings. In addition, the firm is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency.

More recent Antares Pharma, Inc. (NASDAQ:ATRS) news were published by: Globenewswire.com which released: “Antares Pharma Provides XYOSTEDâ„¢ Regulatory Update” on December 21, 2017. Also Globenewswire.com published the news titled: “IMPORTANT ANTARES PHARMA, INC. INVESTOR REMINDER – LEAD PLAINTIFF DEADLINE …” on December 13, 2017. Prnewswire.com‘s news article titled: “Quotidian Technical Highlights on Selected Medical Supplies Stocks — Antares …” with publication date: December 15, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: